Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.63 |
| ▸ | CTSK | P43235 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920111 | 1.00 | CTSS (0.63) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20045974 | 0.91 | PPARG (0.53) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14803767 | 0.91 | PPARG (0.53) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14405376 | 0.91 | CTSS (0.67) | CTSSCTSKLY96MAPTCTSL | |
| SCHEMBL2076110 | 0.91 | CTSS (0.67) | CTSSCTSKLY96MAPTCTSL | |
| SCHEMBL309644 | 0.91 | CTSS (0.67) | CTSSCTSKLY96MAPTCTSL | |
| SCHEMBL30374091 | 0.89 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL539574 | 0.89 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL2574440 | 0.89 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL539575 | 0.89 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AG (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4583925-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335461-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-111315746-B | Tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same | 光州科学技术院 | 2022-11-29 | — | — | CN | disclosed |
| CN-114616229-A | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-113840825-A | Aldose reductase inhibitors | 应用治疗公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-111315746-A | Novel tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same | 光州科学技术院 | 2020-06-19 | — | — | CN | disclosed |
| CN-101948552-A | Linear polystyrene-supported chiral oxazolidine-2-selenium ketone and preparation method thereof | UNIV HUBEI | 2011-01-19 | — | — | CN | disclosed |
| CN-101914174-A | Linear polystyrene-supported (4S)-oxazolidine-2-benzimine as well as preparation method and application thereof | UNIV HUBEI | 2010-12-15 | — | — | CN | disclosed |
| CN-1301964-C | Inhibitors of alpha 4-mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| US-6593338-B2 | Inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. | CELLTECH R&D LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| US-20020137935-A1 | 3-Substituted 2,7-naphthyridin-1-yl derivatives | CELLTECH R&D LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| CN-1098409-A | 2-piperazinone compounds and application thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137935-A1 | 3-Substituted 2,7-naphthyridin-1-yl derivatives | ITGB2, ICAM1, ITGB1 | CTSS 2273/4885CTSK 3047/4885CYP1A2 999/4885 |
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | GBA1, GBA3, GLS2 | CTSS 386/4885CTSK 1543/4885CYP1A2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.